U.S. Markets open in 42 mins
  • S&P Futures

    -57.75 (-1.71%)
  • Dow Futures

    -538.00 (-1.97%)
  • Nasdaq Futures

    -171.25 (-1.48%)
  • Russell 2000 Futures

    -33.80 (-2.13%)
  • Crude Oil

    -1.84 (-4.65%)
  • Gold

    -32.50 (-1.70%)
  • Silver

    -0.85 (-3.46%)

    -0.0064 (-0.5394%)
  • 10-Yr Bond

    -0.0250 (-3.21%)
  • Vix

    +4.44 (+13.68%)

    -0.0119 (-0.9149%)

    -0.0410 (-0.0392%)

    -494.31 (-3.61%)
  • CMC Crypto 200

    +0.41 (+0.16%)
  • FTSE 100

    -108.56 (-1.89%)
  • Nikkei 225

    -75.79 (-0.32%)

3 Healthcare Stocks To Watch On Thursday

CORAL GABLES, FL / ACCESSWIRE / October 25,2018 / Healthcare stocks have helped to boost the US equity markets today. The Select Sector SPDR Healthcare ETF (XLV) has had a strong recovery on Thursday and the broader markets are also surging. The healthcare industry has seen a shakeup recently as new technology innovation and further research on new drugs pushes industry margins. Furthermore, the number of healthcare services deals among institutional investors nearly doubled from 2012 to 2017 as McKinsey & Co. counted 225 deals in 2012 and 510 in 2017. This reflected a compound annual growth rate of 18%.

As healthcare spending is projected to increase 6 percent a year through 2025, the growth of senior Americans and the incidence of chronic disease continues to rise. McKinsey & Co. expects demand to remain favorable in the healthcare sector. Meanwhile, the fragmentation of providers in the healthcare industry means there is plenty of opportunity for investment. With a new birth of positive trading of healthcare stocks, we're looking at three companies that could be ready to follow suit including Premier Health Group, Inc. (PHGRF)(PHGI.CN), Fate Therapeutics, Inc. (FATE), and La Jolla Pharmaceutical Company (LJPC).

Premier Health Group, Inc. (PHGRF)(PHGI.CN), has focused on expanding through strategic deals with other public health companies. Earlier this month, Premier announced that it has selected Reliq Health Technologies Inc. as its exclusive technology partner. Premier's HealthVue primary care clinics will be provided with a HealthVue-branded telemedicine, remote monitoring & AI solution for its clinical staff and more than 100,000 active patients. Reliq Health Technologies is a healthcare technology company that specializes in developing innovative software solutions for the Community Care market.

Statistics from Premier Health Group, Inc. (PHGRF)(PHGI.CN)'s subsidiary, HealthVue show that roughly 15% of Canadians aged 12 and older don't have a primary care physician. Nearly two-thirds of seniors are also unable to get a same-or next-day appointment. This contributes to about 7 in 10 Canadians avoiding seeing a doctor when they are sick. "The HealthVue patient app powered by Reliq Health's technology platform will allow patients to book appointments, see their GP or a specialist via telemedicine, review their own chart, chat with clinic staff and pharmacists, refill prescriptions, and share health data collected in the home with their HealthVue care team," said Dr. Essam Hamza, MD, CEO of HealthVue.

For More Information On Premier Health Group, Click Here

Fate Therapeutics, Inc. (FATE) saw a boost in its share price on Thursday. After opening the day at $11.64, the company's stock reached highs of $12.90 before noon. The company is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders.

Earlier this month, Fate announced that Wen Bo Wang, Ph.D., a leading expert in the manufacture of pluripotent stem cell-derived cell products, has joined the Company as Senior Vice President, Technical Operations. Dr. Wang brings to Fate Therapeutics more than 18 years of cell therapy leadership, having most recently served as Senior Vice President, Cell Therapy Research & Development at FUJIFILM Cellular Dynamics, Inc. According to Fate, Dr. Wang will be responsible for shaping the Company's manufacturing strategies for its pipeline of off-the-shelf cell-based cancer immunotherapy candidates and scaling the Company's induced pluripotent stem cell (iPSC) product platform to support late-stage clinical and commercial operations.

For More Information On Fate Therapeutics, Click Here

La Jolla Pharmaceutical Company (LJPC) released earnings this week. The company recorded a quarterly loss of $1.93 per share. This compares toloss of $1.19 per share a year ago. These figures are adjusted for non-recurring items. This report represents an earnings surprise of 3.98% compared to streetestiates. A quarter ago, it was expected that this drugmaker would post a loss of $1.91 per share when it produced a loss of $2.02; a surprise of -5.76%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once. On the company's earnings call, George F. Tidmarsh, La Jolla Pharmaceutical Company - President, CEO, Secretary & Director, stated, “We continue to receive encouraging feedback from physicians and KOLs that are already using GIAPREZA. In the -- in commercial use, the clinical profile of GIAPREZA has remained quite favorable with no new safety signals identified. We expect that, like other hospital product launches, the first 12 months will be a period of groundwork, as it takes time to go through the standard multitiered process for hospital-based therapies.”

For More Information On La Jolla Pharmaceutical Company, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2018 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer

Contact Information:


SOURCE: StockPrice.com